-Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolesc...
Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers New ...
Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion wil...
Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-revi...
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad populati...
New operating system enables scientists to move from copilot to autopilot, unifying diverse in silico, wet lab research and scientists to accelerate in...
Enara’s discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically actionable Dark Antigens ...
BD (Becton, Dickinson and Company), a leading medical technology company, will feature the next generation of drug delivery and traceability s...
Neurotronic, Inc., a developer of multi-organ denervation to treat complex cardiovascular and metabolic disease, announced that the first clinical outcom...
Company highlights its global expertise and new and expanded capabilities to help biopharma and biotech customers solve global health challenges Thermo ...
-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose ...
Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, announced the...
Back-to-back Presidential Symposium presentations of ENHERTU from DESTINY-Breast11 and DESTINY-Breast05 demonstrate its potential to become a foundat...
Presidential Symposium will feature DESTINY-Breast11 and DESTINY-Breast05, underscoring potential of ENHERTU® (fam-trastuzumab deruxtecan-nxki) in ...
© 2025 Biopharma Boardroom. All Rights Reserved.
